Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research - a consensus document from six scientific societies [Corrigendum]

• Published in: International journal of chronic obstructive pulmonary disease Vol. 14; pp. 247 - 248
• Main Authors: Rossi, Andrea, Butorac Petanjek, Bojana, Chilosi, Marco, Cosio, Borja, Flezar, Matjaz, Koulouris, Nikolaos, Marin, Jose M, Miculinic, Neven, Polese, Guido, Samaržija, Miroslav, Škrgat, Sabina, Vassilakopoulos, Theodoros, Vukić Dugac, Andrea, Zakynthinos, Spyridon, Miravitlles, Marc
• Format: Journal Article
• Language: English
• Published: London Dove Medical Press Ltd 01-01-2019; Dove Medical Press
• Subjects: Corrigendum
• ISSN: 1178-2005; 1176-9106; 1178-2005
• DOI: 10.2147/COPD.S194433

Rossi A, Butorac-Petanjek B, Chilosi M, Cosío BG, Flezar M, Koulouris N, Marin J, Miculinic N, Polese G, Samaržija M, Skrgat S, Vassilakopoulos T, Vukić-Dugac A, Zakynthinos S, Miravitlles M. Int J Chron Obstruct Pulmon Dis. 2017;12: 593–2610. Page 2604, Disclosure, the text “The authors report no conflicts of interest in this work” should read “BGC has received speaker fees from Chiesi, Novartis, Menarini, AstraZeneca, Esteve and Rovi; research grants from Chiesi and Boehringer; and served on advisory boards for Chiesi, Novartis, AstraZeneca and Esteve. MM has received speaker fees from Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, CSL, Behring, Grifols and Novartis; consultancy fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratories Esteve, Mereo BioPharm, Verona Pharma, pH Pharma, Novartis and Grifols; and research grants from GlaxoSmithKline and Grifols. The authors report no other conflicts of interest in this work”.